• ABT-263 (Navitoclax): Advancing Apoptosis in Cancer Research

  2026-06-08

  Explore how ABT-263 (Navitoclax) empowers translational researchers to dissect and manipulate apoptotic pathways in cancer biology. This article blends mechanistic insights, recent breakthroughs in NAD metabolism and senescence bypass, and practical workflow recommendations, delivering strategic guidance far beyond typical product pages. Learn how APExBIO’s ABT-263 uniquely positions your oncology research at the forefront of mechanistic and translational innovation.

• NSC-23766: Rac GTPase Inhibitor for Precision Cell Analysis

  2026-06-07

  NSC-23766 trihydrochloride, a selective Rac GTPase inhibitor, empowers researchers to dissect Rac1-driven signaling with high specificity. Its unique mode of action and robust performance in apoptosis induction and cell cycle arrest make it an indispensable tool for cancer research and advanced cell signaling workflows.

• Technical Guide: AZD8055 as a Selective mTOR Inhibitor in Re

  2026-06-06

  AZD8055 is a highly selective, ATP-competitive mTOR kinase inhibitor designed for dissecting mTORC1 and mTORC2 signaling in preclinical models. It is best used in mechanistic studies of cancer and metabolic signaling pathways, but should not be employed in projects where clinical efficacy endpoints are the primary objective due to limited translational success.

• DGLA-Induced Ferroptosis via ACSL4 in AML: Mechanisms and Im

  2026-06-05

  This study demonstrates that exogenous dihomo-γ-linolenic acid (DGLA) triggers ferroptosis in acute myeloid leukemia (AML) cells through ACSL4-mediated lipid metabolic reprogramming. The findings illuminate a metabolic vulnerability in AML, suggesting new strategies for overcoming chemotherapy resistance.

• Alternariol in Mycotoxin Research: Pathways, Protocols, and

  2026-06-05

  Explore how Alternariol (AOH) advances mycotoxin research through its unique molecular pathways, assay optimization, and role as a tool for cytochrome P450 enzyme and apoptosis studies. This in-depth article bridges protocol design with cutting-edge findings for translational applications.

• Chlorpromazine Hydrochloride: Enhanced Workflows in Antipsyc

  2026-06-04

  Chlorpromazine hydrochloride from APExBIO is a cornerstone for precise dopamine receptor and antiemetic studies, with new insights into hepatic nanoparticle interactions transforming its application landscape. This article delivers advanced workflow guidance, protocol optimization, and troubleshooting solutions for researchers leveraging chlorpromazine in CNS and liver models.

• Murine RNase Inhibitor: Reliable RNA Degradation Prevention

  2026-06-04

  Murine RNase Inhibitor from APExBIO delivers robust, oxidation-resistant RNA protection for sensitive workflows like real-time RT-PCR and cDNA synthesis—even in low DTT environments. Its specificity and stability enable reproducible, high-fidelity results across research applications, from plant extracellular RNA analysis to advanced transcriptomics.

• Direct Enzymatic Synthesis of Fatty Amines from Trilaurin Su

  2026-06-03

  This article examines a recent study demonstrating highly selective, one-pot enzymatic synthesis of medium and long-chain fatty amines from renewable triglycerides such as trilaurin. The approach overcomes longstanding drawbacks of traditional chemical routes, providing a sustainable protocol with high yields and broad implications for lipid engineering and industrial chemistry.

• Dabigatran Etexilate: Direct Thrombin Inhibitor for Atrial F

  2026-06-03

  Dabigatran etexilate is a potent, selective oral direct thrombin inhibitor. It is widely used as an anticoagulant for atrial fibrillation research, with well-defined pharmacokinetics and a clear thrombin inhibition mechanism. Its rapid onset, predictable effects, and favorable safety profile distinguish it from vitamin K antagonists.

• WTAP-Mediated Glutaminase Splicing Drives Ferroptosis Resist

  2026-06-02

  This study uncovers how EGFR-AKT signaling in hepatocellular carcinoma (HCC) promotes WTAP-mediated alternative splicing of glutaminase, leading to metabolic reprogramming that suppresses ferroptosis. The findings highlight m6A-dependent GLS isoform switching as a mechanistic driver of tumor resistance and suggest new metabolic intervention points for HCC therapy.

• Diethylmaleate: Mechanistic Insight for Redox and Resistance

  2026-06-02

  Explore how Diethylmaleate enables translational researchers to dissect oxidative stress, redox regulation, and insecticide resistance mechanisms. This thought-leadership article integrates mechanistic insights, strategic guidance, and protocol recommendations—including highlights from recent GST inhibition studies in Megalurothrips usitatus—while contextualizing the role of high-purity Diethylmaleate from APExBIO in advancing oxidative stress and toxicology research.

• siRNA Nanoparticles Target TDRD9 to Mitigate P. aeruginosa I

  2026-06-01

  This study introduces hyaluronic acid-coated siRNA nanoparticles that target Tudor domain-containing protein 9 (TDRD9), promoting neutrophil cuproptosis and alleviating Pseudomonas aeruginosa-induced lung injury in preclinical models. The approach reveals a previously uncharacterized immune modulation mechanism with implications for bacterial pneumonia therapy.

• Acetylcholine Chloride in Cholinergic Signaling Pathway Rese

  2026-06-01

  Acetylcholine Chloride is the primary neuromuscular junction neurotransmitter and a key agent in studying cholinergic signaling. Its high purity and solubility support precise modeling of gut-brain axis mechanisms relevant to pediatric epilepsy. Evidence links enhanced cholinergic transmission to seizure suppression in translational models.

• BipD-Mediated Hijacking of Host Mitophagy in B. pseudomallei

  2026-05-31

  This study reveals how Burkholderia pseudomallei utilizes its virulence factor BipD to hijack the host's KLHL9/KLHL13/CUL3 E3 ligase complex, driving ubiquitination of IMMT and initiating mitophagy for bacterial survival. The findings expand our understanding of pathogen-induced mitochondrial quality control and provide a mechanistic link between the ubiquitin-proteasome system and innate immune evasion.

• Macrophage EP4 Deficiency Accelerates Atherosclerosis via CD

  2026-05-30

  This study uncovers how macrophage-specific loss of EP4 receptor intensifies atherosclerosis progression by enhancing CD36-mediated lipid uptake and pro-inflammatory macrophage polarization. The research elucidates the cellular mechanisms underlying plaque growth and instability, offering valuable insights for cardiovascular disease models and targeted intervention strategies.

460 records 16/31 page Previous Next First page 上5页 1617181920 下5页 Last page